Yuhan Corporation
Clinical trials sponsored by Yuhan Corporation, explained in plain language.
-
New drug targets Hard-to-Treat lung and solid tumors
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors that have certain genetic changes (HER2 or EGFR). The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 161 participants will receive the drug, and…
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated May 17, 2026 08:15 UTC
-
New hope for Hard-to-Treat HER2 cancers: first human trial begins
Disease control Recruiting nowThis early-stage study is testing a new drug called YH32367 in people with advanced HER2-positive solid tumors that have spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. About 147 participants will take part…
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New hope for chronic hives sufferers: experimental drug lesigercept in human trials
Symptom relief Recruiting nowThis study tests a new drug called lesigercept for people with chronic spontaneous urticaria (long-term hives) that antihistamines don't fully control. About 150 adults will receive either the drug or a placebo for 12 weeks to see if it reduces itching and welts. The goal is to f…
Phase: PHASE2 • Sponsor: Yuhan Corporation • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
New drug YH35995 tested in healthy volunteers for safety
Knowledge-focused Recruiting nowThis early-stage study tests a new oral drug, YH35995, in healthy adult men to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. The goal is to gather …
Phase: PHASE1 • Sponsor: Yuhan Corporation • Aim: Knowledge-focused
Last updated May 11, 2026 20:40 UTC